{"preliminary_commentary":{"by_channel":{"x_thread":4,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"FIRST-308","nct_id":"NCT05948475","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=first-308-nct05948475. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FIRST-308","arms":[{"description":"Tinengotinib will be administered in 28-day cycles.","label":"Tinengotinib 8 mg QD","type":"EXPERIMENTAL"},{"description":"Tinengotinib will be administered in 28-day cycles.","label":"Tinengotinib 10 mg QD","type":"EXPERIMENTAL"},{"description":"Physician's Choice treatments include FOLFOX or FOLFIRI","label":"Physician's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Cholangiocarcinoma"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tinengotinib 8 mg","otherNames":[],"type":"DRUG"},{"name":"Tinengotinib 10 mg","otherNames":[],"type":"DRUG"},{"name":"Physician's Choice","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-06","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","official_title":"A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: Incidence, duration, and severity of adverse events (AEs)","timeFrame":"Up to 30 days from study discontinuation"},{"measure":"Part B: PFS by BICR","timeFrame":"From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months"}],"references":[],"start_date":{"date":"2023-12-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","url":"https://clinicaltrials.gov/study/NCT05948475"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/first-308-nct05948475"}